Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis

Tinea Pedis Clinical Trial

Official title:

A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-500 in Subjects With Tinea Pedis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00750139
• Other study ID #: MUS 90200-0736/1
• Status: Completed
• Phase: Phase 3
• First received: September 8, 2008
• Last updated: April 19, 2013
• Start date: August 2008
• Est. completion date: December 2009

Study information

• Verified date: April 2013
• Source: Merz Pharmaceuticals, LLC
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

A research study to compare the safety and effectiveness of an investigational medication called NAFT-500 to placebo, when used in subjects with tinea pedis (athlete's foot).

Description:

To evaluate the efficacy and safety of NAFT-500 compared to placebo in the treatment of subjects with potassium hydroxide (KOH) and culture positive symptomatic tinea pedis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 707
• Est. completion date: December 2009
• Est. primary completion date: August 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

1. Review and sign a statement of Informed Consent and HIPAA authorization.

2. For minors (less than 18 years), the parent/legal guardian must complete the informed consent process AND the subject must complete the assent process and sign the appropriate form (if age appropriate).

3. Males or non-pregnant females =12 years of age, of any race or sex. Females of childbearing potential must have a negative urine pregnancy test.

4. Presence of tinea pedis on one or both feet characterized by clinical evidence of a tinea infection (at least moderate erythema, moderate scaling, and mild pruritus)based on signs and symptoms.

5. KOH positive and culture positive baseline skin scrapings obtained from the site most severely affected or a representative site of the overall severity.

6. Subjects must be in good health and free from any clinically significant disease that might interfere with the study evaluations.

7. Subject must be able to understand the requirements of the study and willing to comply with the study requirements.

Exclusion Criteria:

1. A life-threatening condition (ex. autoimmune deficiency syndrome, cancer, unstable angina, or myocardial infarction) within the last 6 months.

2. Subjects with abnormal findings - physical or laboratory - that are considered by the investigator to be clinically important and indicative of conditions that might complicate interpretation of study results.

3. Subjects with a known hypersensitivity to study medications or their components.

4. Subjects who have a recent history or who are currently known to abuse alcohol or drugs.

5. Uncontrolled diabetes mellitus.

6. Hemodialysis or chronic ambulatory peritoneal dialysis therapy.

7. Current diagnosis of immunocompromising conditions.

8. Foot psoriasis, corns and/or callus involving any web spaces, atopic or contact dermatitis.

9. Severe dermatophytoses, onychomycosis (on the evaluated foot), mucocutaneous candidiasis, or bacterial skin infection.

10. Extremely severe tinea pedis (incapacitating).

11. Female subject who is pregnant or lactating, who is not using or does not agree to use an acceptable form of contraception during the study, or who intends to become pregnant during the study (females who are surgically sterilized or post menopausal for at least 2 years are not considered to be of childbearing potential).For the purposes of this study, acceptable forms of birth control include: oral contraceptives, contraceptive patches/implants, double barrier methods (e.g., use of condom and spermicide), IUD, and abstinence with second acceptable method should subject become sexually active.

12. Subjects using the following medications:

• Topical anti-fungal therapy, foot/shoe powders, or topical corticosteroids applied to the feet within 14 days prior to randomization. Topical terbinafine, butenafine,and naftifine within 30 days prior to randomization

• Oral anti-fungal therapies 3 months (8 months for oral terbinafine) prior to randomization

• Systemic antibiotic or corticosteroid treatment within 30 days of randomization

• Any other significant treatments, except hormonal contraception and multivitamin, at the discretion of the investigator that would interfere with study treatment.

• Investigational drug within 30 days of randomization

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Athlete's Foot
• Tinea
• Tinea Pedis

Intervention

Drug:
• NAFT-500
topical cream 1 application every day up to 4 weeks weeks
• Placebo 2-weeks
placebo cream 1 application every day for up to 4 weeks
• Naftin 1%
topical allylamine cream applied once a day for up to 4 weeks
• Placebo 4-weeks
topical placebo cream applied once a day for up to 4 weeks

Locations

Country	Name	City	State
United States	Radiant Research	Birmingham	Alabama
United States	Glazer Dermatology	Buffalo Grove	Illinois
United States	J & S Studies	College Station	Texas
United States	Research Across America	Dallas	Texas
United States	Haber Dermatology	Euclid	Ohio
United States	Silverton Skin Institute	Grand Blanc	Michigan
United States	Zoe Draelos, MD	High Point	North Carolina
United States	Dr. Felix Sigal	Los Angeles	California
United States	FXM Research	Miami	Florida
United States	FXM Research	Miramar	Florida
United States	Coastal Carolina Research Center	Mt. Pleasant	South Carolina
United States	Tulane University Health Services	New Orleans	Louisiana
United States	Paddington Testing Company	Philadelphia	Pennsylvania
United States	Temple University School of Podiatric Medicine	Philadelphia	Pennsylvania
United States	Research Across America	Plano	Texas
United States	Oregon Dermatology and Research Center	Portland	Oregon
United States	University of California San Francisco, Dept of Dermatology	San Francisco	California

Sponsors (1)

Lead Sponsor	Collaborator
Merz Pharmaceuticals, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Subjects With Complete Cure at Week 6.	The first primary efficacy variable was the percentage of subjects in the NAFT-500 Cream, 2% or 2-week placebo groups with complete cure at Week 6.; The second primary efficacy variable was the percentage of subjects in the Naftin 1% Cream or 4-week placebo groups with complete cure at Week 6.; Complete cure was defined as negative mycology results from the central laboratory (dermatophyte culture and KOH) and absence of erythema, scaling, and pruritus that were evaluated using a 4 point severity scale.	Week 6	No
Secondary	Percentage of Subjects With Mycological Cure and Percentage of Subjects With Treatment Effectiveness at Week 6	Mycological Cure was defined as negative KOH result and negative dermatophyte culture at Week 6. Treatment Effectiveness was defined as negative KOH, negative culture, and Scaling, Erythema, and Pruritus grades of 0 or 1 at Week 6.	Week 6	No